Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

2º Parcial RM > Trials > Flashcards

Trials Flashcards

(47 cards)

Start Studying
1
Q

Experimental studies are the best methods to

A

Support cause-effect relationships

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Differences with observational studies

A

Researcher introduces / manipulates the exposure

Much more validity if the assignment of the exposure is random and the sample size sufficiently large

Exposure doesn’t exist before starting the trial

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Disadvantages of the experimental studies

A

Can only answer very limited range of questions (strict rules, no variability) about variety of doses, combinations of doses / exposures, long-term exposures, special effects in subgroups of peculiar patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Features of experimental studies

A

Last steps in research
Measure efficacy (ideal circumstances) not effectiveness (real circumstances)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Types of trials

A

Clinical trials
Field trials
Cluster trials

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Clinical trials

A

Participants randomly allocated are patients with a previous disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Field trials

A

Participants are initially free of disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Cluster trials

A

The unit of randomization is a group (it should be a large number size)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Phase I trials tests

A

If a new treatment is safe and look for the best way to give it

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Phase I trials focus

A

Safety and tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Phase I trials participants

A

20-80 healthy volunteers

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Phase I trials features

A

No control group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Phase II trials test

A

Response of the disease to a new treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Phase II trials provide

A

Preliminary information on efficacy, dose-response and add information on tolerance

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Phase II trials participants

A

100-200 patients with disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Phase IIa trials

A

Pilot study
Small sample
Healthy and diseased

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Phase IIb trials

A

Usually controlled
Test efficacy
Only patients

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Phase III trials test

A

Is a new treatment is better than a standard one

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Phase III trials provide

Study These Flashcards
A

The definitive answer for efficacy and safety

20
Q

Phase III trials features

Study These Flashcards
A

Large sample size
Needs sufficient duration
Always controlled
Randomized
In medical journals

21
Q

Phase IV trials provide

Study These Flashcards
A

Information about long-term benefits and side effects

22
Q

Phase IV trials features

Study These Flashcards
A

Post-marketing

23
Q

Designs of clinical trials

Study These Flashcards
A

Cross-over trials
Factorial design

24
Q

Cross-over trials

25
Factorial design
26
Aim of clinical trials
Explanatory / pragmatic trials Superiority / equivalence / non-inferiority trials
27
Explanatory trials
Strict inclusion criteria Ideal setting of “experimental” conditions
28
Pragmatic trials
Wide (lax) inclusion criteria Real conditions
29
Superiority trial
Refutation of null hypothesis (both treatments are equal) leads to the conclusion that one of them is superior
30
Equivalence trial
Demonstrate that A and B are equal (efficacies are close enough from a clinical / practical point of view)
31
Non-inferiority trials
Demonstrate at least same efficacy Only look to one bound of CI One-tailed tests
32
Placebo effect
Sum of non-specific effect of the physician, non-specific effect of the drug and regression to the mean
33
Distingish placebo effect from pharmacodynamic effect
This makes it possible to substract the placebo effect from the efficacy attributed to the treatment being evaluated.
34
Randomization
Assigning participants to the different study groups by a random (unpredictable) mechanism
35
Randomization of a large number of subjects tend to produce
Identical groups with respect to known characteristic as well as unknown characteristics
36
The only between-group difference in randomized groups will be
Intervention to which subjects have been assigned -> all differences in outcomes will be specifically due to that intervention = strong causal inference
37
Features of randomization
Gold standard for showing causality Eliminates biased assignment of treatments Facilitates blind evaluation of the outcomes Allows statistical test that assume randomly distributed differences under the null hypothesis
38
Conditions for randomization
Sufficient large sample size Truly random assignment method Masking of the random sequence (MRS)
39
Ransom sampling vs random allocation (randomization)
Random sampling: small subset (sample) is selected (drawn) Random allocation: all the study subjects are distributed in groups
40
Problem in randomization
Conflict emerges between the clinician’s role and the aim of a clinical trial, and as a result, unintentional biases may occur: clinicians may be tempted to cheat (to help patients)
41
Restricted randomization
Random allocation can be made in blocks -> keep sizes of groups similar Stratified randomization: 1º stratifying the whole study population into subgroups with the characteristics (strata) then simple random sampling from the stratifies groups
42
Masking of the random sequence (MRS)
Does not allow to guess to know what group will go the next patient (unpredictability). This is done at the beginning of the trial.
43
Blinding of the intervention when assessing outcomes (BIWAO)
Investigators responsible for assessing or adjudicating the outcomes do not know the allocated group. Particularly important when assessing subjective outcomes (pain or anxiety)
44
Intention to treat (ITT)
Analysis of the results of the trial that follows the initial random group assignment Resembles the reality of clinical practice where patients not always comply Biases the results towards the null value (potential benefit underestimated)
45
Per protocol (P-P)
Analysis that only includes compliers (advantage of randomization is eliminated Any difference tends to be exaggerated Better for equivalence studies
46
Integrim vs subgroup
Interim: repeated provisional analyses meanwhile the trial is on-going Subgroup: analyses only including a subset of participants. If the effect is not present in the overall sample, there is not much justification to defend the effect within a subgroup Both require lower p values (instead of p<.05) for achieving statistical significance.
47
Important consideration for randomized trials
Despite their high internal validity they have low external validity (low ability to generalize their results)

2º Parcial RM (8 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions